Table 2.
Representative studies that evaluated the biological effects of Src inhibitors on basic cellular events associated with prostate cancer progression.
| Reference | Cell lines | Inhibitors | Decreased proliferation | Decreased migration | Decreased adhesion | Apoptosis | Decreased tumoral xenograft growth |
|---|---|---|---|---|---|---|---|
| (45) | DU-145 | PD173955 | Yes | – | – | – | – |
| (36) | DU-145 | PP2 | – | Yes | – | – | – |
| PC-3 | |||||||
| LNCaP | |||||||
| (46) | PC-3 | CGP77675 | Yes | Yes | Yes | No | – |
| CGP76080 | |||||||
| (47) | PC-3 | Compound 1 | Yes | – | – | – | – |
| (5) | DU-145 | Lyn-inhibiting peptides | Yes | – | – | Yes | Yes |
| PC-3 | |||||||
| (6) | DU-145 | Dasatinib | – | Yes | Yes | – | – |
| (23) | LNCaP | PP1 | Yes (androgen-dependent proliferation) | – | – | – | – |
| (32) | PC-3 | SI35 | Yes | Yes | Yes | – | – |
| SI40 | |||||||
| (48) | DU-145 | Resveratrol | Yes | – | – | Yes | – |
| (9) | DU-145 | Saracatinib | Yes | Yes | – | – | Yes |
| PC-3 | |||||||
| (43) | PC-3-MM32GL | Dasatinib | Yes | Yes | – | Yes | Yes (and decreased lymphatic spread) |
| PC-3-AR-A1 | |||||||
| LNCaP | |||||||
| (49) | DU-145 | Bosutinib | Yes | Yes | Yes | – | Yes (and decreased bone metastases) |
| PC-3 | |||||||
| (50) | DU-145 | Dasatinib | Yes | Yes | – | – | Yes (and decreased angiogenesis) |
| PC-3 | |||||||
| LNCaP | |||||||
| (44) | CWR22 | Dasatinib | – | – | – | – | Yes (androgen-independent growth) |
| KX01 | |||||||
| (33) | PC-3 | Dasatinib | – | Yes | – | – | – |
| (51) | PC-3 | CTA095 | Yes | Yes | – | Yes | Yes |